875 related articles for article (PubMed ID: 28622052)
1. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
[TBL] [Abstract][Full Text] [Related]
2. Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study.
Menzella F; Galeone C; Ruggiero P; Bagnasco D; Catellani C; Facciolongo N
Pulm Pharmacol Ther; 2020 Feb; 60():101874. PubMed ID: 31857207
[TBL] [Abstract][Full Text] [Related]
3. [Patients in the IDEAL cohort: A snapshot of severe asthma in France].
Taillé C; Pison C; Nocent C; Devouassoux G; Prud'homme A; Gruber A; Gunsoy N; Albers F
Rev Mal Respir; 2019 Feb; 36(2):179-190. PubMed ID: 30429093
[TBL] [Abstract][Full Text] [Related]
4. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
[TBL] [Abstract][Full Text] [Related]
5. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
Respir Med; 2019; 154():69-75. PubMed ID: 31220806
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
[TBL] [Abstract][Full Text] [Related]
7. Real-world Omalizumab and Mepolizumab treated difficult asthma phenotypes and their clinical outcomes.
Fong WCG; Azim A; Knight D; Mistry H; Freeman A; Felongco M; Kyyaly A; Harvey M; Dennison P; Zhang H; Howarth P; Arshad SH; Kurukulaaratchy RJ
Clin Exp Allergy; 2021 Aug; 51(8):1019-1032. PubMed ID: 33866615
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
[TBL] [Abstract][Full Text] [Related]
9. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
[TBL] [Abstract][Full Text] [Related]
10. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
[TBL] [Abstract][Full Text] [Related]
11. Anti-IgE and Anti-IL5 Biologic Therapy in the Treatment of Nasal Polyposis: A Systematic Review and Meta-analysis.
Rivero A; Liang J
Ann Otol Rhinol Laryngol; 2017 Nov; 126(11):739-747. PubMed ID: 28918644
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study.
Pérez de Llano LA; Cosío BG; Domingo C; Urrutia I; Bobolea I; Valero A; Entrenas Costa LM; Quirce S; Barranco P; Marina Malanda N; Andrés LP; Alvarez-Gutiérrez FJ
J Allergy Clin Immunol Pract; 2019; 7(7):2277-2283.e2. PubMed ID: 30677539
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma].
Kolbin AS; Avdeev SN; Zhuravleva MV; Gomon YM; Balykina YE; Matveyev NV; Proskurin MA; Fedosenko SV
Ter Arkh; 2019 Dec; 91(12):47-56. PubMed ID: 32598589
[TBL] [Abstract][Full Text] [Related]
14. Severe asthma: When to resort to biological agents.
Tenero L; Rossignoli S; Piacentini G
Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
[TBL] [Abstract][Full Text] [Related]
15. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
16. Eligibility for treatment with omalizumab in Italy and Germany.
Buhl R; Marco AG; Cohen D; Canonica GW
Respir Med; 2014 Jan; 108(1):50-6. PubMed ID: 24315468
[TBL] [Abstract][Full Text] [Related]
17. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
[TBL] [Abstract][Full Text] [Related]
18. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
[TBL] [Abstract][Full Text] [Related]
19. Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Akenroye A; Nopsopon T; Hacker JJ; Laidlaw TM
Sci Rep; 2024 May; 14(1):10404. PubMed ID: 38710930
[TBL] [Abstract][Full Text] [Related]
20. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
